Antiplatelet Therapy in the Secondary Prevention of Non-cardioembolic Ischemic Stroke and Transient Ischemic Attack: A Mini-Review

Martin Vališ, Blanka Klímová*, Michal Novotný and Roman Herzig

Department of Neurology, Faculty of Medicine and University Hospital Hradec Kralove, Charles University, Hradec Kralove, Czechia

The aim of this mini-review is to discuss the main antiplatelet agents that have been successfully used in the secondary prevention of non-cardioembolic ischemic stroke and transient ischemic attacks (TIA). The methodology is based on a literature review of available peer-reviewed English studies listed in PubMed. The findings reveal that aspirin remains a reliable antiplatelet agent in the secondary prevention of acute non-cardioembolic ischemic stroke and TIA. Nevertheless, currently, there are also other agents, i.e., ticagrelor, clopidogrel, and cilostazol, that can be applied. In addition, the results indicate that time is significant not only in severe stroke but also in non-severe stroke and TIA, which suggests that antiplatelet therapy should be applied within 24 h after the first symptoms because early treatment can lead to an improvement in neurological outcomes and reduce the chance of an early subsequent stroke.

Keywords: ischemic stroke, transient ischemic attack, aspirin, clopidogrel, cilostazol, ticagrelor, dipyridamole, antiplatelet therapy

INTRODUCTION

Strokes are among the major causes of morbidity, mortality, and long-term disability (1). As stated by Béjot et al. (2), monthly mortality from strokes in Europe ranges from 13 to 35%. In addition, in European Union countries, the number of patients with strokes is expected to grow by 27% between 2017 and 2047. The reason for this is that there has been an increase in aging population groups and better survival rates after a stroke (3).

The most frequent type of stroke, comprising on average between 80 and 90% of all strokes, is ischemic stroke (4). This type of stroke results from the occlusion of the artery that supplies blood to the brain. The occlusion decreases blood flow and oxygen to the brain, contributing to harm or death of brain cells. If the circulation is not reestablished quickly, the brain damage can be permanent (5). The severity of ischemic stroke ranges from clinically mild (i.e., a minor stroke or transient ischemic attack [TIA]) to very severe (i.e., a major ischemic stroke), but the underlying causes are identical (6). The initial manifestations of ischemic stroke and TIA are often followed by recurrent vascular events, including recurrent strokes (7).

At present, antiplatelet therapy is crucial in the management of non-cardioembolic ischemic stroke and TIA, representing approximately 80% of all acute ischemic cerebrovascular events (8), and in their prevention (9), which is very important since repeated strokes occur in 10–20% of patients within 3 months after the first stroke (1).
Antiplatelet agents are usually preferred over anticoagulant agents due to their connection with lower rates of intracranial hemorrhage and moderately lower global death rates. Antiplatelet monotherapy is usually favored over dual antiplatelet therapy (DAPT) because DAPT is often associated with severe bleeding complications (10). The guidelines of the American Heart Association and American Stroke Association suggest antiplatelet monotherapy with aspirin within 24–48 h of an acute ischemic stroke. The recommended doses range between 160 and 300 mg per day (11). Despite aspirin being suggested as therapy for acute ischemic stroke, it does not succeed in preventing platelet aggregation in 5–55% of patients (12). Nevertheless, the administration of DAPT immediately following a minor ischemic stroke (NIHSS score of ≤3) or high-risk TIA (ABC2D score of ≥4) may be beneficial and outweigh the risks in patients with acute minor ischemic stroke or high-risk TIA. In this respect, the guidelines suggest 21-day treatment with aspirin and clopidogrel to be started within 24 h of symptoms onset with minor stroke. However, this combination should not be administered immediately after intravenous thrombolysis (IVT) (11).

Furthermore, two independent multicenter, randomized, double-blind, placebo-controlled trials have established the efficacy of short-term DAPT to prevent recurrent ischemic stroke in patients with minor stroke or high-risk TIA. The CHANCE trial (Clopidogrel in High-Risk Patients with Acute Non-disabling Cerebrovascular Events) in the Chinese population demonstrated a 32% reduction in recurrent stroke in the first 30 days of treatment (13). In the POINT trial (Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke), conducted in North America, Europe, Australia, and New Zealand, up to 90 days after the index event, DAPT was associated with a 28% reduction in ischemic stroke (which was higher during the first 30 days of treatment) but was also associated with a higher number of major hemorrhages (14). However, in both trials (CHANCE and POINT), the loading dose of clopidogrel was given before the initiation of DAPT. In addition, researchers have also found that DAPT (aspirin with clopidogrel) may be ineffective in 5–30% of patients with percutaneous coronary interventions, mostly due to clopidogrel resistance. This number increases to 66% in patients with neuro-interventional events (15). Recently, Steffel et al. (16) discovered that rivaroxaban plus aspirin was associated with fewer adverse cardiovascular events but more major bleeding events than aspirin alone.

To date, clinical studies have provided evidence about four antiplatelet agents: aspirin, aspirin-dipyridamole, clopidogrel, and ticagrelor (9), which have also been widely described in clinical practice guidelines (11).

The purpose of this mini-review is therefore to provide an update on the main antiplatelet agents that have been successfully used in the secondary prevention of non-cardioembolic ischemic stroke and TIA, as well as to explore whether novel and effective antiplatelet agents and strategies have occurred in the secondary prevention of non-cardioembolic ischemic stroke and TIA.

METHODS AND MATERIALS

The authors of this mini-review conducted a literature search of peer-reviewed English language research articles listed in PubMed. The articles were searched using the following keywords: antiplatelet therapy AND stroke, antiplatelet therapy AND ischemic stroke, antiplatelet agents AND ischemic stroke, antiplatelet therapy AND transient ischemic attack, antiplatelet agents AND transient ischemic attack. The search was performed for studies published between January 1, 2015, and August 31, 2020, because several review studies on this topic summarized the literature prior to this period [cf. (17–19)]. The authors also conducted a backward search, i.e., they searched the references of the studies identified for relevant research studies that could have been missed during the PubMed searches. Only randomized controlled studies were included in the final analysis and evaluation.

RESULTS

Altogether, 11 randomized controlled trials (RCTs) were detected in PubMed and during the backward searches of the reference lists of the selected studies. Four studies originated in Japan, two in China, one in the UK, one in the USA, and one in Thailand, and two were multinational RCTs. The number of patients ranged from 21 to 13,199. The intervention period lasted from 1 week to 4 years. In all studies, aspirin was used either alone or with another antiplatelet drug. The most common were clopidogrel and cilostazol. The remaining antiplatelet drugs included in the studies were ticagrelor and dipyridamole. Cilostazol was exclusively used in studies of Asian origin, while clopidogrel was used across different continents. Table 1 below provides the basic characteristics of these drugs apart from the use of dipyridamole, which is now considered to be obsolete.

Furthermore, the use of individual antiplatelet agents and their combinations in the detected studies are described below.

Monotherapy: A recent study states that dual therapy is more beneficial than monotherapy. This corresponds to the fact that in the literature in recent years, we found very few studies of monotherapy. Amarenco et al. (7) demonstrated the superiority of ticagrelor (6.7%; p = 0.017) over aspirin (9.6%) in the prevention of stroke, myocardial infarction, and death after aspiration (9.6%) in patients with acute ischemic stroke or a transient ischemic attack at 90 days (HR 0.68; 95% CI 0.53–0.88; p = 0.003). Haungsaihtong et al. (22) evaluated changes in mean platelet volume (MPV) after the use of four antiplatelet drugs (aspirin, clopidogrel, aspirin plus dipyridamole and cilostazol) in patients with acute non-cardioembolic ischemic stroke to assess the effect of antiplatelet therapy and MPV on the stroke outcome. The authors concluded that after 4 weeks of therapy, MPV was reduced, as well as the NIHSS score, but only clopidogrel reduced this score with statistical significance (p = 0.003).

Dual therapy: aspirin plus clopidogrel—this combination is the most common in the literature. Jing et al. (23) divided patients into three research subgroups (those with multiple acute infarctions, single acute infarctions and no acute infarctions) and compared the effect of dual therapy and monotherapy in
these groups in terms of recurrent stroke. In the group with multiple acute infarctions, recurrent stroke occurred in the following percentage of patients: 10.1% (dual therapy) and 18.1% (aspirin alone), i.e., HR, 0.5; 95% CI, 0.3–0.96 (p = 0.04). In the group with single acute infarctions, no difference between dual therapy and aspirin alone was observed, i.e., 8.9 vs. 8.5% (HR, 1.1; 95% CI, 0.6–2.0; p = 0.71). For the no acute infarctions group, the results were as follows: 2.6% (dual therapy) vs. 1.4% (aspirin alone), i.e., HR, 1.7; 95% CI, 0.3–11.1 (p = 0.56). The authors concluded that dual clopidogrel and aspirin therapy appears to have the most significant clinical benefit for patients with multiple acute infarctions.

Johnston et al. (14), based on a clinical study, reported that dual therapy vs. aspirin alone was associated with a lower risk of a severe ischemic event of 5.0 vs. 6.5%, i.e., HR 0.75; 95% CI, 0.59–0.95 (p = 0.02). He et al. (24) examined a group of patients with minor stroke or transient ischemic attack (TIA) to compare dual therapy vs. aspirin monotherapy for neurological deterioration, recurrent stroke, or stroke development in patients with a TIA within 14 days of admission. During the 2-week period, worsening of stroke occurred in nine patients in the dual therapy group and 19 patients in the monotherapy group. Stroke occurred after the TIA in one patient in the dual therapy group and in three patients in the monotherapy group. The authors concluded that early dual therapy can reduce neurological deterioration in patients with acute ischemic stroke as compared to monotherapy.

Dual therapy: aspirin plus ticagrelor—Amarenco et al. (26) evaluated the combination of ticagrelor and aspirin (as opposed to aspirin alone) in stroke prevention. The main endpoint was the time to stroke (progression of the event or a new stroke) or death within 30 days. Disabling stroke was defined by a modified Rankin Scale score (mRS) > 1. A score of mRS > 1 occurred in the following percentage of patients: 4.0% (dual therapy) vs. 4.7% (aspirin alone), i.e., HR, 0.83; 95% CI, 0.69–0.99 (p = 0.04). Based on this study, it appears that ticagrelor added to aspirin was superior to aspirin alone in preventing disabling stroke or death at 30 days and reduced the total burden of disability owing to ischemic stroke recurrence.

The key findings reveal that DAPT appears to be safe and effective in decreasing the risk of multiple ischemic strokes, particularly in the long term and with larger sample sizes (27), as well as being more effective than monotherapy in the early stages of acute ischemic stroke (24). This has also been confirmed by the most recent study by Amarenco et al. (26), in which patients with TIA and minor ischemic stroke received ticagrelor in combination with aspirin to prevent disabling stroke or death at 30 days. The results showed that DAPT was more efficient than aspirin alone in decreasing the total burden of disability due to ischemic stroke recurrence. However, the results differed in the risk of hemorrhage. While Jing et al. (23) and Toyoda et al. (27) confirmed a reduced risk of severe bleeding after 3 months, Johnston et al. (14) found the opposite result. Furthermore, the results indicated that the triple combination had no gains with
respect to the occurrence and severity of recurrent stroke but actually had a higher rate of hemorrhage (28).

**DISCUSSION**

Our review of the literature revealed that aspirin is a reliable antiplatelet agent in the secondary prevention of acute non-cardioembolic ischemic stroke and TIA and that it is the only drug that has received a class IA recommendation (11). However, Amarenco et al. (7), within the SOCRATES project, indicated that if ticagrelor was administered within 24 h of symptom onset, it would be more effective than aspirin in preventing stroke, myocardial infarction, or death at 90 days in patients with acute ischemic stroke or a transient ischemic attack when associated with potentially symptomatic ipsilateral atherosclerotic stenosis. Their findings also showed that there were no differences in the rate of life-threatening bleeding or major or minor bleeding episodes in patients with ipsilateral stenosis in the ticagrelor group compared with the aspirin group.

Haungsaitthong et al. (22) reported that clopidogrel considerably decreased the NIHSS score ($p = 0.003$), and it resulted in the greatest reduction in MPV compared with the others. However, their study was quite small and followed the patients for only 4 weeks. Nevertheless, their findings were also confirmed by Paciaroni et al. (29) in their recent meta-analysis, in which they revealed smaller risks of severe undesirable cardiovascular or cerebrovascular episodes, recurrent stroke, and bleeding episodes for clopidogrel monotherapy compared to aspirin. These results confirmed the clinical benefits of antiplatelet monotherapy with clopidogrel over aspirin for secondary prevention in patients with a recent ischemic stroke.

In secondary prevention, dual antiplatelet therapy appears to be the best solution. A combination of aspirin and clopidogrel seems to be beneficial not only shortly (24 h to 1 week) after an acute non-cardioembolic stroke, most often a minor ischemic stroke, or a high-risk TIA (24) but also throughout the first 90 days after the event (14, 23, 27). These findings have also been confirmed by other studies (30, 31). Rahman et al. (30) stated that DAPT with aspirin and clopidogrel significantly reduced the risk of recurrent IS in the short-term ($RR_{\text{short-term}} = 0.53; \ 95\% \ CI_{\text{short-term}} = 0.37–0.78$) and intermediate-term ($RR_{\text{intermediate-term}} = 0.72; \ 95\% \ CI_{\text{intermediate-term}} = 0.58–0.90$). In addition, their findings also proved that intermediate-term ($RR_{\text{intermediate-term}} = 2.58; \ 95\% \ CI = 1.19–5.60$) and long-term ($RR_{\text{long-term}} = 1.87; \ 95\% \ CI = 1.36–2.56$) aspirin and clopidogrel regimens significantly increased the risk of major bleeding compared to short-term aspirin and clopidogrel, as revealed by Johnston et al. (14). The same findings were reported by Greving et al. (32). In their meta-analysis, they stated that a combination of clopidogrel and aspirin is beneficial for long-term secondary prevention after a non-cardioembolic stroke or transient ischemic attack, regardless of the patient characteristics. However, this combination is connected with a considerably higher risk of major bleeding than other DAPT.

Hao et al. (33) further found that DAPT with aspirin and clopidogrel administered within 24 h after high-risk TIA or minor ischemic stroke decreases the incidence of subsequent stroke by ~20 in 1,000 people, with a possible increase in moderate to severe bleeding of 2 per 1,000 population.

Furthermore, the evaluation of the detected trial (28) revealed that triplet antiplatelet therapy did not have any superiority over DAPT regarding the recurrence of strokes. In contrast, the rate of hemorrhage was much higher in these patients than in those who received fewer medications.

We also found that monotherapies with aspirin or ticagrelor and DAPT with aspirin and clopidogrel are mainly used in western Europe and the USA, while cilostazol, either alone or combined with aspirin, is predominantly used in Asia [cf. (34)]. However, the experts assume that there is no reason to test cilostazol in Europe and the USA since it has a good safety profile and seems safer than aspirin and is probably safer than other antithrombotic drugs in terms of reducing bleeding complications, especially hemorrhagic strokes.

The limitations of the included studies include their different sample sizes, various lengths of intervention periods, sometimes slightly different dosages of antiplatelet drugs, and an absence of sufficiently long follow-up periods in some studies.

Overall, the findings reveal that aspirin is a reliable antiplatelet agent in the secondary prevention of acute non-cardioembolic ischemic stroke and TIA. Nevertheless, currently, there are also other agents, i.e., ticagrelor, clopidogrel, and cilostazol, that can be applied. In addition, the results indicate that time is significant not only in severe stroke but also in non-severe stroke and TIA, which suggests that antiplatelet therapy should be administered within 24 h after the first symptoms (after 24 h in patients treated with IVT) because early treatment can lead to an improvement in neurological outcomes and a decrease in the risk of early subsequent stroke.

Future research should focus on identifying more effective drugs that could be developed for use in monotherapy because dual therapy only increases the rate of adverse events related to polypharmacy. In addition, these novel molecules could increase the risk of excessive bleeding. In fact, currently, a few studies are being conducted on this topic (Table 1).

**AUTHOR CONTRIBUTIONS**

MV, BK, MN, and RH equally contributed to the whole concept of the article, its methodology, data processing, and drafting and revision. All authors agreed with this final version of the manuscript.

**FUNDING**

This work was supported in part by the Ministry of Health of the Czech Republic (DRO – UHHK 00179906) and Charles University, Czech Republic (PROGRES Q40/15).
REFERENCES

1. Albay CEQ, Leyson FGD, Cheng FC. Dual versus mono antiplatelet therapy for acute non-cardioembolic ischemic stroke or transient ischemic attack, an efficacy and safety analysis - updated meta-analysis. BMC Neurol. (2020) 20:224. doi: 10.1186/s12883-020-01808-y

2. Béjot Y, Bailly H, Durier J, Giroud M. Epidemiology of stroke in Europe and trends for the 21st century. Presse Med. (2016) 45:e391–8. doi: 10.1016/j.pjnm.2016.10.003

3. Wafa HA, Wolfe CDA, Emmett E, Roth GA, Johnson CO, Wang Y. Burden of stroke in Europe. Thirty-year projections of incidence, prevalence, deaths, and disability-adjusted life years. Stroke. (2020) 51:2418–27. doi: 10.1161/STROKEAHA.120.029606

4. Johns Hopkins Medicine. Types of Strokes and Stroke Risks. (2020). Available online at: https://www.hopkinsmedicine.org/centers_clinics/cerebrovascular/stroke/stroke_types_risk.html (accessed September 10, 2020).

5. Healthline. (2020). Available online at: https://www.healthline.com/health/stroke/cerebral-ischemia (accessed September 10, 2020).

6. Warsitz MA, Schwellnus H, Hildebrandt M, Hornig M, Walther C. Diagnosis and management of acute ischemic stroke: speed is critical. CMAJ. (2015) 187:887–93. doi: 10.1503/cmaj.140355

7. Amarenco P, Albers GW, Denison H, Easton JD, Evans SR, Held P, et al. Efficacy and safety of ticagrelor versus aspirin in acute stroke or transient ischemic attack of atherosclerotic origin: a subgroup analysis of SOCRATES, a randomised, double-blind, controlled trial. Lancet Neurol. (2017) 16:F301–10. doi: 10.1016/S1474-4422(17)30083-8

8. Warlow C, Sudlow C, Dennis M, Wardlaw J, Sandercock P, et al. Guidelines for the early management of patients with acute ischaemic stroke: 2019 update to the 2018 Guidelines for the early management of acute ischaemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. (2019) 50:e344–418. doi: 10.1161/STR.0000000000000211

9. Hackam DG, Spence JD. Antiplatelet therapy in ischemic stroke and transient ischemic attack. Stroke. (2019) 50:773–8. doi: 10.1161/STROKEAHA.118.023954

10. Pace WD, Earl A, Bryant C, Hansen C. Antiplatelet Therapy for Secondary Prevention of Ischemic Stroke. (2020). Available online at: https://www.uspharmacist.com/article/antiplatelet-therapy-for-secondary-prevention-of-ischemic-stroke (accessed September 10, 2020).

11. Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker KN, et al. Guidelines for the early management of patients with acute stroke: 2019 update to the 2018 Guidelines for the early management of acute ischaemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. (2019) 50:e344–418. doi: 10.1161/STR.0000000000000211

12. Huangsaithong R, Udommongkol C, Nidhinandana S, Chairungsi J, Chiravanur Y, Suwantaname J, et al. The changes in mean platelet volume after using of antiplatelet drugs in acute ischemic stroke: a randomized controlled trial. J Med Assoc Thai. (2015) 8:852–7.

13. Jing J, Meng X, Zhao X, Liu L, Wang A, Pan Y, et al. Dual antiplatelet therapy in transient ischemic attack and minor stroke with different infarction patterns: subgroup analysis of the CHANCE randomized clinical trial. JAMA Neurol. (2018) 75:711–9. doi: 10.1001/jamaneurol.2018.0247

14. He F, Xia C, Zhang JH, Li XQ, Zhou ZH, Li FP, et al. Clopidogrel plus aspirin versus aspirin alone for preventing early neurological deterioration in patients with acute ischemic stroke. J Clin Neurosci. (2015) 22:83–6. doi: 10.1016/j.jocn.2014.05.038

15. Aoki J, Iuchi Y, Urabe T, Yamagami H, Todo K, Fujimoto S, et al. Acute aspirin plus cilostazol dual therapy for noncardioembolic stroke patients within 48 hours of symptom onset. J Am Heart Assoc. (2019) 8:e012652. doi: 10.1161/JAHA.119.012652

16. Amarenco P, Denison H, Evans SR, et al. Ticagrelor added to aspirin in acute ischemic stroke or transient ischemic attack in prevention of disabling stroke: a randomized clinical trial. JAMA Neurol. (2020) 07:2020. doi: 10.1001/jamaneurol.2020.4396

17. Toyoda K, Uchiyama S, Yamaguchi T, Easton JD, Kimura K, Hoshino H, et al. Dual antiplatelet therapy using cilostazol for secondary prevention in patients with high-risk ischemic stroke in Japan: a multicentre, open-label, randomised controlled trial. Lancet Neurol. (2019) 18:539–48. doi: 10.1016/S1474-4422(19)30148-6

18. Bath PM, Woodhouse LJ, Appleton JP, Beridze M, Christensen H, Dineen RA, et al. Triple versus guideline antiplatelet therapy to prevent recurrence after acute ischemic stroke or transient ischemic attack: the TARDIS RCT. Health Technol Assess. (2018) 22:1–76. doi: 10.3310/hta22480

19. Paciaroni M, Ince B, Hu B, Jeng JS, Kutzik L, Liu L, et al. Benefits and risks of clopidogrel vs. aspirin monotherapy after recent ischemic stroke: a systematic review and meta-analysis. Cardiovasc Ther. (2019) 2019:1607181. doi: 10.1155/2019/1607181

20. Rahman H, Khan SV, Nasir F, Hammad T, Meyer MA, Kaluski E. Optimal duration of aspirin plus clopidogrel after ischemic stroke or transient ischemic attack. A systematic review and meta-analysis. Stroke. (2019) 50:947–53. doi: 10.1161/STROKEAHA.118.023978

21. Vela-Duarte D. Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA. (2018). Available online at: https://www.thehospitalist.org/hospitalist/article/189254/neurology (accessed September 10, 2020).

22. Greving JP, Diener HC, Reitsma JB, Bath PM, Csiba L, Hakké W, et al. Antiplatelet therapy after noncardioembolic stroke: an individual patient data network meta-analysis. Stroke. (2019) 50:1812–8. doi: 10.1161/STROKEAHA.118.024497

23. Hao Q, Tampi M, O’Donnell M, Foroutan F, Siemienink RAC, Guyett G. The use of cilostazol for secondary stroke prevention: isn’t it time it’s evaluated in Western countries? Expert Opin Pharmacother. (2020) 21:381–7. doi: 10.1080/14656566.2019.1707181

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.